The Art of the Biopharma Deal: The China Angle

Sven Agten () and Ben Wu ()

A chapter in Biopharma in China, 2024, pp 101-112 from Springer

Abstract: Abstract Over the last years foreign companies have been very active in partnership and cooperation deals with Chinese biopharma companies and healthcare investors. Anybody who wants to raise money from Chinese investors or strike a partnering or cooperation deal with Chinese companies however, needs to understand what investors or Chinese pharma companies are looking for. And because of the vast differences and needs of the Chinese healthcare and pharmaceutical market, the value proposition towards China can be very different than other markets. The most reputable and well-known USD-denominated healthcare funds in China are originally from the US, but have very specific funds to invest in China or ex-US. Then there are the strategic investors who are actively investing in, and in-licensing assets from foreign companies. There are mainly two categories of strategic investors: the newly established, venture capital backed biopharma companies, and the traditional Chinese pharmaceutical companies. It’s important to understand the background of these companies. The traditional pharma companies are not rooted in innovation, and as such are not always that familiar with the process of drug discovery. The newly established biopharma companies on the other hand are well versed in innovation, but of course don’t have the established sales network as the big pharma companies. Just like the US or Europe, Chinese investors have also engaged in incubating or building new biopharma companies. As a matter of fact at the height of the biotech investment boom, almost all Chinese biotechs have been incubated by healthcare venture capitalists, and were not spun out from universities or research institutes, as is often the case in the US or Europe.. As such it’s important to understand that incubation or new venture building in China is fundamentally different than in Europe or the US. Lastly it’s important to understand what diseases are more prevalent in China, or which technologies are more needed than others.

Keywords: China angle; Foreign Direct Investment (FDI); Fund; Incubation; In-licensing; Investment; Partnering; Regional rights; Strategic investor; Value proposition (search for similar items in EconPapers)
Date: 2024
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:sprchp:978-981-97-1471-1_5

Ordering information: This item can be ordered from
http://www.springer.com/9789819714711

DOI: 10.1007/978-981-97-1471-1_5

Access Statistics for this chapter

More chapters in Springer Books from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().